MapLight Therapeutics, Inc.
49.90%
27,536,011
1770069
Aug 13, 2026
Aug 18, 2026, 06:51 PM
Reporting Persons (4)
This is a joint filing. The reported shares may overlap between reporting persons and should not be summed.
| Name | Type | % of Class | Aggregate | Sole Voting | Shared Voting |
|---|---|---|---|---|---|
| Catalyst4, Inc. | CO | 49.90% | 27,536,011 | 27,536,011 | 0 |
| Robert Brown | Individual | 49.90% | 27,536,011 | 0 | 27,536,011 |
| Ekemini Riley | Individual | 49.90% | 27,536,011 | 0 | 27,536,011 |
| Mark Vorsatz | Individual | 49.90% | 27,536,011 | 0 | 27,536,011 |
Disclosure Items (6)
Common Stock, $0.0001 par value per share
MapLight Therapeutics, Inc.
800 Chesapeake Drive, Redwood City, CA, 94063
Item 3 of the Original Schedule 13D is amended as follows: The aggregate purchase price for the shares acquired in the PIPE Offering (as defined below) by the Reporting Persons was $83,400,153.82. The source of these funds was the working capital of Catalyst4.
Item 5 of the Original Schedule 13D is amended as follows: (c) Except as previously reported on Amendment No. 1 filed with the Commission on August 3, 2026 and as set forth above in Item 4 (which is incorporated herein by reference), none of the Reporting Persons has effected any transactions of the Issuer's voting common stock during the 60 days preceding the date of this report, except as described in Item 4 and Item 6 of this Schedule 13D which information is incorporated herein by reference.
Item 6 of the Original Schedule 13D is hereby amended as follows: The information set forth in Items 3 and 4 of this Statement is incorporated herein by reference. In connection with its purchase of shares of the Issuer's voting common stock, Catalyst and certain of the Issuer's other investors entered into a Registration Rights Agreement (the "Registration Rights Agreement") with the Issuer. The terms and provisions of the Registration Rights Agreement are described more fully in the Issuer's Current Report on Form 8-K filed with the Commission on August 14, 2026, and the above summary is qualified by reference to such description and the full text of the Registration Rights Agreement, which is filed as Exhibit 99.6 and is incorporated herein by reference.
Exhibit 99.4 Form of Securities Purchase Agreement, dated August 13, 2026, by and among MapLight Therapeutics, Inc. and the Purchasers. (filed as Exhibit 10.1 to the Issuer's Current Report on Form 8-K as filed with the Commission on August 13, 2026 and incorporated herein by reference) Exhibit 99.5 Form of Pre-Funded Warrant. (filed as Exhibit 4.1 to the Issuer's Current Report on Form 8-K as filed with the Commission on August 13, 2026 and incorporated herein by reference) Exhibit 99.6 Form of Registration Rights Agreement, dated August 13, 2026, by and among MapLight Therapeutics, Inc. and the Purchasers. (filed as Exhibit 10.2 to the Issuer's Current Report on Form 8-K as filed with the Commission on August 13, 2026 and incorporated herein by reference)